Fundamental Analysis of CIBUS INC(NASDAQ:CBUS) stock

Fundamental Rating

Overall CBUS gets a fundamental rating of 2 out of 10. We evaluated CBUS against 565 industry peers in the Biotechnology industry. CBUS has a bad profitability rating. Also its financial health evaluation is rather negative. CBUS is valued quite expensively, but it does show have an excellent growth rating.

Quickly go to:

1. Profitability

1.1 Basic Checks

CBUS had negative earnings in the past year.

CBUS had a negative operating cash flow in the past year.

CBUS had negative earnings in each of the past 5 years.

CBUS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -121.07%, CBUS is doing worse than 80.93% of the companies in the same industry.

CBUS's Return On Equity of -411.87% is on the low side compared to the rest of the industry. CBUS is outperformed by 78.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-121.07%
ROE	-411.87%
ROIC	N/A

ROA(3y)-67.69%

ROA(5y)-63.77%

ROE(3y)-177.62%

ROE(5y)-143.55%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBUS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CBUS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CBUS has more shares outstanding

Compared to 5 years ago, CBUS has more shares outstanding

Compared to 1 year ago, CBUS has an improved debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -3.06, we must say that CBUS is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -3.06, CBUS perfoms like the industry average, outperforming 49.20% of the companies in the same industry.

A Debt/Equity ratio of 0.00 indicates that CBUS is not too dependend on debt financing.

CBUS has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: CBUS outperforms 47.95% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-3.06

ROIC/WACCN/A

WACC10.47%

2.3 Liquidity

CBUS has a Current Ratio of 1.44. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.

CBUS has a worse Current ratio (1.44) than 81.64% of its industry peers.

CBUS has a Quick Ratio of 1.44. This is a normal value and indicates that CBUS is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.44, CBUS is doing worse than 80.93% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.44
Quick Ratio	1.44

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CBUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -71.73%.

The Revenue has grown by 446.45% in the past year. This is a very strong growth!

The Revenue has been growing by 49.91% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-71.73%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-379.87%

Revenue 1Y (TTM)446.45%

Revenue growth 3Y-57.61%

Revenue growth 5Y49.91%

Sales Q2Q%251.58%

3.2 Future

Based on estimates for the next years, CBUS will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.23% on average per year.

The Revenue is expected to grow by 182.70% on average over the next years. This is a very strong growth

EPS Next Y84.15%

EPS Next 2Y37.05%

EPS Next 3Y24.01%

EPS Next 5Y15.23%

Revenue Next Year116.73%

Revenue Next 2Y170.03%

Revenue Next 3Y191.71%

Revenue Next 5Y182.7%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

CBUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year CBUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as CBUS's earnings are expected to grow with 24.01% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y37.05%

EPS Next 3Y24.01%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CBUS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CIBUS INC

NASDAQ:CBUS (11/22/2024, 8:00:02 PM)

After market: 4.14 0 (0%)

4.14

-0.23 (-5.26%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap122.30M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-121.07%
ROE	-411.87%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.01

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.44
Quick Ratio	1.44
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-71.73%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y84.15%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)446.45%

Revenue growth 3Y-57.61%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CIBUS INC (CBUS)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens